TY  - JOUR 
AU  - Aparicio, Cristina
AU  - Queipo, Mónica
AU  - Belver, Marina
AU  - Espeso, Francisco
AU  - Serna-Pérez, Julia
AU  - Enríquez-Rodríguez, Lucía
AU  - Acebal, Carlos
AU  - Martín-Muñoz, Álvaro
AU  - Valeri, Antonio
AU  - Leivas, Alejandra
AU  - Río, Paula
AU  - Powell, Daniel J.
AU  - Lobo-Valentín, Rosa
AU  - Arrabal, David
AU  - Martínez-López, Joaquín
AU  - Sánchez, Ana
AU  - de la Fuente, Miguel Á.
AU  - González-Vallinas, Margarita
PY  - 2025
SN  - 2072-6694
UR  - https://uvadoc.uva.es/handle/10324/81890
AB  - Chimeric Antigen Receptor (CAR)-T cell therapy has shown significant success in treating hematological cancers, but commercialized autologous CAR-T therapies face challenges such as high costs, manufacturing delays, complex standardization and the...
LA  - eng
PB  - Multidisciplinary Digital Publishing Institute
KW  - Linfocitos T
KW  - Alogénico
KW  - Off-the-shelf
KW  - Tumores sólidos
KW  - Memoria inmunológica
KW  - CRISPR
KW  - NKG2D
KW  - Interleuquinas
KW  - Inmunoterapia
KW  - Cancer
KW  - Receptor de antígeno quimérico (CAR)
TI  - A novel early memory-enriched allogeneic NKG2D CAR-T cell therapy based on CRISPR/Cas9 technology for solid tumors
DO  - 10.3390/cancers17193186
ER  -